Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)

Roy­al­ty Phar­ma ex­ecs shed light on strat­e­gy be­hind their first gene ther­a­py deal

A deal with Fer­ring Phar­ma­ceu­ti­cals last month rep­re­sent­ed Roy­al­ty Phar­ma’s first for­ay in­to gene ther­a­py roy­al­ties, and it’s al­ready rais­ing ques­tions about whether it rep­re­sents …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.